Table 3

Baseline DAS28-CRP

Study acronymStudy groupBaseline DAS28-CRP*
GO-REVEAL13Golimumab 50 mgMean 5.0SD 1.1
Golimumab 100 mgMean 4.9SD 1.1
PlaceboMean 4.9SD 1.0
OPAL BROADEN17Tofacitinib 5 mgMean 4.6SD 0.9
Tofacitinib 10 mgMean 4.5SD 1.0
AdalimumabMean 4.4SD 1.0
PlaceboMean 4.5SD 1.0
FUTURE 121Secukinumab 150 mgMean 4.8SD 1.1
Secukinumab 75 mgMean 4.9SD 1.2
PlaceboMean 4.9SD 1.1
FUTURE 222Secukinumab 300 mgMean 4.8SD 1.0
Secukinumab 150 mgMean 4.9SD 1.1
Secukinumab 75 mgMean 4.7SD 1.0
PlaceboMean 4.7SD 1.0
FUTURE 323Secukinumab 300 mgMean 4.5SD 1.0
Secukinumab 150 mgMean 4.6SD 1.1
PlaceboMean 4.7SD 1.1
FUTURE 424Secukinumab 150 mg with loading regimenMean 4.5SD 1.0
Secukinumab 150 mg without loading regimenMean 4.5SD 1.1
PlaceboMean 4.6SD 1.0
FUTURE 525Secukinumab 300 mgMean 4.5SD 1.0
Secukinumab 150 mg with loading doseMean 4.7SD 1.0
Secukinumab 150 mg without loading doseMean 4.6SD 1.1
PlaceboMean 4.6SD 1.1
PSUMMIT 126Ustekinumab 45 mgMedian 5.2IQR 4.6–5.7
Ustekinumab 90 mgMedian 5.2IQR 4.6–5.8
PlaceboMedian 5.2IQR 4.4–6.0
PSUMMIT 228Ustekinumab 45 mgMedian 5.6IQR 4.9–6.3
Ustekinumab 90 mgMedian 5.3IQR 4.7–6.0
PlaceboMedian 5.2IQR 4.4–5.9
ASTRAEA31AbataceptMean 5.0SD 1.1
PlaceboMean 4.9SD 1.1
OPAL BEYOND33Tofacitinib 5 mgMean 4.5SD 1.0
Tofacitinib 10 mgMean 4.7SD 1.2
PlaceboMean 4.4SD 1.0
PALACE 134Apremilast 20 mgMean 4.8SD 1.1
Apremilast 30 mgMean 4.9SD 1.0
PlaceboMean 4.9SD 1.0
PALACE 235Apremilast 20 mgMean 4.6SD 1.0
Apremilast 30 mgMean 4.7SD 1.0
Apremilast 30 mgMean 4.5SD 1.1
PALACE 336Apremilast 20 mgMean 4.6SD 1.1
Apremilast 30 mgMean 4.6SD 1.0
PlaceboMean 4.5SD 1.1
PALACE 437Apremilast 20 mgMean 4.7SD 1.1
Apremilast 30 mgMean 4.5SD 1.0
PlaceboMean 4.6SD 1.1
  • *The DAS28-CRP combines a tender joint count based on a 28-joint assessment, swollen joint count based on a 28-joint assessment, in addition to the general health patient global Visual Analogue Scale (in mm) domains and CRP (in mg/L).40

  • DAS28-CRP, Disease Activity Score 28 using C reactive protein.